A New Formulation of an Old Drug: A Potential New Therapy in the Management of Oral cGvHD.
Oral chronic graft versus host disease (cGVHD) is often refractory to systemic therapies. Additional topical treatment is commonly required. The potency of the agent, the vehicle and formulation in which it is delivered are all critical factors in determining the effectiveness of topical therapies. High potency of budesonide, combined with its very low bioavailability when absorbed through mucosal surfaces, increased the potential role in topical application for oral cGVHD. Viscous formulation increases mucosal contact time resulting in a greater decrease in mucosal inflammation. This short communication suggests that oral viscous budesonide should be considered as a potential new therapy in the management of oral cGVHD.
*Department of Pediatrics, University of Bologna, S. Orsola-Malpighi Hospital, Bologna †Pediatric Unit Fabrizio Spaziani Hospital, Frosinone ‡Pediatric Gastroenterology Unit, International Hospital Salvator Mundi, Rome, Italy.
Luca
L
Bertelli
Giovanni
G
Di Nardo
Daniele
D
Zama
Giulia
G
Bardasi
William
W
Morello
Riccardo
R
Masetti
Tamara
T
Belotti
Maria Luisa
ML
Forchielli
Arcangelo
A
Prete
Andrea
A
Pession
D000287:Administration, Topical; D019819:Budesonide / Q000008:administration & dosage* / Q000493:pharmacokinetics; D002648:Child; D002908:Chronic Disease; D005260:Female; D006086:Graft vs Host Disease / Q000188:drug therapy*; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects; D006801:Humans; D009059:Mouth Diseases; D009061:Mouth Mucosa / Q000473:pathology; D019226:Oral Ulcer
D019819:Budesonide